Psivant Therapeutics has a differentiated pipeline of targets with high biological and disease validation that have historically provided challenges for the design of therapeutics.
Best-in-Class Small Molecules
Target
Area of Focus
Exploratory
Discovery
Pre-Clinical
WEE1/MYT1
Dual WEE1/MYT1 Inhibitor
Focus:
Oncology
Status:
Discovery
IRAK1/IRAK4
Dual IRAK1/IRAK4 Inhibitor
Focus:
Inflammation
Status:
Discovery
Undisclosed
Allosteric Inhibitor
Focus:
Inflammation and Immunology
Status:
Discovery
Undisclosed
Allosteric Inhibitor
Focus:
Inflammation and Immunology
Status:
Discovery
Undisclosed
Allosteric Inhibitor
Focus:
Inflammation and Immunology
Status:
Discovery
Undisclosed
Allosteric Inhibitor
Focus:
Inflammation and Immunology
Status:
Exploratory
Target
Area of Focus
Exploratory
Discovery
Pre-Clinical
WEE1/MYT1
Dual WEE1/MYT1 Inhibitor
Focus: Oncology
Status: Discovery
IRAK1/IRAK4
Dual IRAK1/IRAK4 Inhibitor
Focus: Inflammation
Status: Discovery
Undisclosed
Allosteric Inhibitor
Focus: Inflammation and Immunology
Status: Discovery
Undisclosed
Allosteric Inhibitor
Focus: Inflammation and Immunology
Status: Discovery
Undisclosed
Allosteric Inhibitor
Focus: Inflammation and Immunology
Status: Discovery
Undisclosed
Allosteric Inhibitor
Focus: Inflammation and Immunology
Status: Exploratory
Target Animations by Istvan Kolossvary